報價延遲最少15分鐘:2026/06/06 22:22 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.48/-1.28
|
|
企業價值
1.50B
|
| 資產負債 |
|
每股賬面淨值
6.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
123.67M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC). |
